HSPA5 and acute lymphoblastic leukemia: The first peptide-drug conjugate PEP-DOX is competent in killing chemotherapy-resistant B-lineage ALL cells by targeting the surface expressed HSPA5 and constitutively active anti-apoptotic UPR pathway.